The short interest data are out for the most recent settlement date, January 15. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big potential upside and big potential downside.
As we have said before, FDA rulings can make or break the biotech stocks, and short sellers and mega-bulls often go to war against each other in these companies. After all, if a single failed clinical trial can mean disaster for a stock, then some short sellers can argue for a stock implosion down the road.
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The January 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Amgen Inc. (NASDAQ: AMGN) saw its short interest decrease to 9.42 million shares from the previous level of 9.91 million. Shares were last seen trading at $222.95, in a 52-week range of $166.30 to $244.99.
Short interest in Biogen Inc. (NASDAQ: BIIB) shrank to 3.60 million shares from the previous 4.33 million. The stock recently traded at $281.14, within a 52-week range of $215.78 to $338.87.
Gilead Sciences Inc. (NASDAQ: GILD) saw its short interest fall to 17.78 million shares from 21.30 million in the previous period. Shares were trading at $63.83, in a 52-week range of $60.89 to $70.50.
The number of MannKind Corp. (NASDAQ: MNKD) shares short increased to 40.76 million. The previous reading was 40.29 million. The stock traded at $1.62 a share, in a 52-week range of $1.02 to $2.34.
Alexion Pharmaceuticals Inc.’s (NASDAQ: ALXN) short interest rise to 4.80 million shares from the previous 4.66 million. Shares were trading at $105.30, in a 52-week range of $94.59 to $141.86.
Get Ready To Retire (Sponsored)
Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Get started right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
